FindMyKOL
Clinical trialNCT04230109RecruitingPhase 2Interventional

Sacituzumab Govitecan In TNBC

SponsorMassachusetts General HospitalEnrollment239ER-Negative Breast CancerHER2-negative Breast CancerInvasive Breast CancerPR-Negative Breast CancerTriple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    Active, not recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Sara Tolaney, MD, MPH
    Recruiting
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Laura Spring, MD
    Recruiting
  • Massachusetts General Hospital - North Shore Cancer Center

    Danvers, Massachusetts, United States

    Therese Mulvey, MD
    Recruiting
  • Massachusetts General Hospital at Newton-Wellesley Hospital

    Newton, Massachusetts, United States

    Amy Comander, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →Sacituzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
14 Jul 2020
Primary completion
31 Oct 2028
Completion
31 Oct 2029
Last update posted
17 Jul 2026
Registered enrollment
239
Registry id
NCT04230109
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.